Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEBNASDAQ:GNTAOTCMKTS:HSTCNASDAQ:PYXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$1.65-2.1%$1.25$0.80▼$3.08$69.02M-0.9819,269 shs75,188 shsGNTAGenenta Science$3.98+4.7%$3.97$2.74▼$7.28$69.50M0.5916,797 shs11,621 shsHSTCHST Global$0.30$0.65$0.23▼$1.10$17.39M-1.24175 shsN/APYXSPyxis Oncology$1.14+3.6%$1.19$0.83▼$5.39$68.14M1.13734,339 shs617,104 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-3.52%+14.24%+52.31%+67.86%-36.49%GNTAGenenta Science+2.87%+30.49%-20.56%+11.80%+28.65%HSTCHST Global0.00%0.00%-63.73%-63.73%-70.78%PYXSPyxis Oncology+2.24%+3.64%-15.56%+29.94%-60.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals2.1823 of 5 stars3.53.00.00.00.01.70.0GNTAGenenta Science1.8256 of 5 stars3.53.00.00.00.61.70.0HSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/APYXSPyxis Oncology1.2039 of 5 stars3.41.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 3.00Buy$5.50234.35% UpsideGNTAGenenta Science 3.00Buy$25.00528.14% UpsideHSTCHST Global 0.00N/AN/AN/APYXSPyxis Oncology 2.80Moderate Buy$9.00689.47% UpsideCurrent Analyst Ratings BreakdownLatest HSTC, GNTA, ANEB, and PYXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AGNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AHSTCHST GlobalN/AN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/A$2.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%9/23/2025 (Estimated)GNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AHSTCHST Global-$150K-$0.02N/A∞N/AN/AN/AN/AN/APYXSPyxis Oncology-$77.33M-$1.59N/AN/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)Latest HSTC, GNTA, ANEB, and PYXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A25.2925.29GNTAGenenta ScienceN/A6.896.89HSTCHST GlobalN/AN/AN/APYXSPyxis OncologyN/A7.757.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%GNTAGenenta Science15.13%HSTCHST GlobalN/APYXSPyxis Oncology39.09%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%GNTAGenenta Science28.99%HSTCHST Global65.82%PYXSPyxis Oncology10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.08 million7.97 millionNot OptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableHSTCHST Global157.77 million19.75 millionNot OptionablePYXSPyxis Oncology6061.95 million55.38 millionOptionableHSTC, GNTA, ANEB, and PYXS HeadlinesRecent News About These CompaniesPyxis Oncology Chief Financial, Operating Officer Pamela Connealy Retires >PYXSJuly 3, 2025 | marketwatch.comPyxis Oncology Appoints New Principal Financial OfficerJuly 3, 2025 | tipranks.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2025 | globenewswire.comPyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14June 19, 2025 | finance.yahoo.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from BrokeragesJune 16, 2025 | marketbeat.comPyxis Oncology Reports Increased Losses Amidst Ongoing R&D InvestmentsMay 30, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)May 22, 2025 | theglobeandmail.comPyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comPyxis Oncology to Participate in Two Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comNew Approaches to Tumor Targeting Are Driving the Next Wave of Oncology BreakthroughsMay 8, 2025 | baystreet.caPyxis Oncology reveals promising preclinical data for cancer drugApril 27, 2025 | investing.comPyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADCApril 25, 2025 | globenewswire.com5 Small Drug Stocks to Buy as Tariff-Related Uncertainty LoomsApril 23, 2025 | zacks.comTop Cancer Stocks to Buy to Boost Your Portfolio's HealthApril 16, 2025 | zacks.comPyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology ForumApril 2, 2025 | globenewswire.comPyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025March 25, 2025 | globenewswire.comStifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)March 24, 2025 | markets.businessinsider.comRBC Capital Remains a Buy on Pyxis Oncology (PYXS)March 20, 2025 | markets.businessinsider.comPyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)March 18, 2025 | markets.businessinsider.comPyxis Oncology (PYXS) Gets a Hold from William BlairMarch 18, 2025 | markets.businessinsider.comPyxis Oncology Advances Cancer Therapeutics with MICVOMarch 18, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSTC, GNTA, ANEB, and PYXS Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$1.64 -0.04 (-2.08%) As of 07/7/2025 03:45 PM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Genenta Science NASDAQ:GNTA$3.98 +0.18 (+4.74%) As of 07/7/2025 04:00 PM EasternGenenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.HST Global OTCMKTS:HSTC$0.30 0.00 (0.00%) As of 07/3/2025HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.Pyxis Oncology NASDAQ:PYXS$1.14 +0.04 (+3.64%) As of 07/7/2025 04:00 PM EasternPyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
